217 related articles for article (PubMed ID: 19811811)
1. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
[TBL] [Abstract][Full Text] [Related]
3. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Chan JK; Brady W; Monk BJ; Brown J; Shahin MS; Rose PG; Kim JH; Secord AA; Walker JL; Gershenson DM
Gynecol Oncol; 2018 Aug; 150(2):247-252. PubMed ID: 29921512
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML
Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040
[TBL] [Abstract][Full Text] [Related]
6. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
Hensley ML; Blessing JA; Mannel R; Rose PG
Gynecol Oncol; 2008 Jun; 109(3):329-34. PubMed ID: 18534250
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
Mahmood ST; Agresta S; Vigil CE; Zhao X; Han G; D'Amato G; Calitri CE; Dean M; Garrett C; Schell MJ; Antonia S; Chiappori A
Int J Cancer; 2011 Oct; 129(8):1963-9. PubMed ID: 21154746
[TBL] [Abstract][Full Text] [Related]
9. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.
Duska LR; Blessing JA; Rotmensch J; Mannel RS; Hanjani P; Rose PG; Dizon DS
Gynecol Oncol; 2014 Oct; 135(1):44-8. PubMed ID: 25091619
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
Choong NW; Kozloff M; Taber D; Hu HS; Wade J; Ivy P; Karrison TG; Dekker A; Vokes EE; Cohen EE
Invest New Drugs; 2010 Oct; 28(5):677-83. PubMed ID: 19649772
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
12. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
[TBL] [Abstract][Full Text] [Related]
13. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
Monk BJ; Blessing JA; Street DG; Muller CY; Burke JJ; Hensley ML
Gynecol Oncol; 2012 Jan; 124(1):48-52. PubMed ID: 21996263
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Reichardt P; Kang YK; Rutkowski P; Schuette J; Rosen LS; Seddon B; Yalcin S; Gelderblom H; Williams CC; Fumagalli E; Biasco G; Hurwitz HI; Kaiser PE; Fly K; Matczak E; Chen L; Lechuga MJ; Demetri GD
Cancer; 2015 May; 121(9):1405-13. PubMed ID: 25641662
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
17. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
Han JY; Kim HY; Lim KY; Han JH; Lee YJ; Kwak MH; Kim HJ; Yun T; Kim HT; Lee JS
Lung Cancer; 2013 Feb; 79(2):137-42. PubMed ID: 23182663
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
Bang YJ; Kang YK; Kang WK; Boku N; Chung HC; Chen JS; Doi T; Sun Y; Shen L; Qin S; Ng WT; Tursi JM; Lechuga MJ; Lu DR; Ruiz-Garcia A; Sobrero A
Invest New Drugs; 2011 Dec; 29(6):1449-58. PubMed ID: 20461441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
